Methylation of TFPI-2 is an early event of esophageal carcinogenesis

Epigenomics

Volumn 4, Issue 2, 2012, Pages 135-146

  Jia, Yan ^a,b   Yang, Yunsheng ^a   Brock, Malcolm V ^c   Cao, Baoping ^a,b   Zhan, Qimin ^d   Li, Yazhuo ^a   Yu, Yuanzi ^a,b   Herman, James G ^c   Guo, Mingzhou ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d CANCER HOSPITAL   (China)

Author keywords

carcinogenesis; DNA methylation; dysplasia; esophageal cancer; TFPI 2

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; TFPI 2 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; ESOPHAGUS CANCER; ESOPHAGUS CARCINOGENESIS; ESOPHAGUS DISEASE; ESOPHAGUS DYSPLASIA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; AGED; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUCOUS MEMBRANE; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC;

EID: 84859198864     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.12.11     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Adams L, Roth MJ, Abnet CC et al. Promoter methylation in cytology specimens as an early detection marker for esophageal squamous dysplasia and early esophageal squamous cell carcinoma. Cancer Prev. Res. (Phila.) 1(5), 357-361 (2008).
3. Toh Y, Oki E, Ohgaki K et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int. J. Clin. Oncol. 15(2), 135-144 (2010).
4. Lin DC, Du XL, Wang MR. Protein alterations in ESCC and clinical implications: a review. Dis. Esophagus 22(1), 9-20 (2009).
5. Zhang XM, Guo MZ. The value of epigenetic markers in esophageal cancer. Front. Med. China 4(4), 378-384 (2010).
6. El-Serag HB, Graham DY, Satia JA, Rabeneck L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am. J. Gastroenterol. 100(6), 1243-1250 (2005).
7. Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J. Gastroenterol. 16(30), 3793-3803 (2010).
8. Guo M, Ren J, Brock MV, Herman JG, Carraway HE. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics 3(6), 336-341 (2008).
9. Kisiel W, Sprecher CA, Foster DC. Evidence that a second human tissue factor pathway inhibitor (TFPI-2) and human placental protein 5 are equivalent. Blood 84(12), 4384-4385 (1994). First report of TFPI-2.
10. Rao CN, Liu YY, Peavey CL, Woodley DT. Novel extracellular matrix-associated serine proteinase inhibitors from human skin fibroblasts. Arch. Biochem. Biophys. 317(1), 311-314 (1995).
11. Tang Z, Geng G, Huang Q et al. Expression of tissue factor pathway inhibitor 2 in human pancreatic carcinoma and its effect on tumor growth, invasion, and migration in vitro and in vivo. J. Surg. Res. 167(1), 62-69 (2011).
12. Gessler F, Voss V, Seifert V, Gerlach R, Kogel D. Knockdown of TFPI-2 promotes migration and invasion of glioma cells. Neurosci. Lett. 497(1), 49-54 (2011). Discusses how TFPI-2 is related to tumor migration and invasion.
13. Nobeyama Y, Okochi-Takada E, Furuta J et al. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int. J. Cancer 121(2), 301-307 (2007).
14. Wang S, Xiao X, Zhou X et al. TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 10, 617 (2010). TFPI-2 is frequently methylated in nasopharyngeal carcinoma.
15. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93(18), 9821-9826 (1996).
16. Jia Y, Yang Y, Liu S, Herman JG, Lu F, Guo M. SOX17 antagonizes WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Epigenetics 5(8), 743-749 (2010).
17. Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin. Hematol. 45(1), 23-30 (2008).
18. Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza- 2′-deoxycytidine in human cancer cell lines. Blood 113(3), 659-667 (2009).
19. George J, Gondi CS, Dinh DH, Gujrati M, Rao JS. Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin. Cancer Res. 13(12), 3507-3517 (2007). Suggests that TFPI-2 may induce apoptosis in glioblastoma.
20. Xu C, Deng F, Mao Z et al. The interaction of the second Kunitz-type domain (KD2) of TFPI-2 with a novel interaction partner, prosaposin, mediates the inhibition of the invasion and migration of human fibrosarcoma cells. Biochem. J. 441(2), 665-674 (2012). Explores the invasion and migration effect of TFPI-2 on fibrosarcoma.
21. Ma S, Chan YP, Kwan PS et al. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Res. 71(2), 583-592 (2011). Demonstrates that miRNA-616 induced prostate cancer cells proliferation by suppressing TFPI-2.
22. Ollivier V, Bentolila S, Chabbat J et al. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 91(8), 2698-2703 (1998).
23. Sprecher CA, Kisiel W, Mathewes S et al. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc. Natl Acad. Sci. USA 91(8), 3353-3357 (1994).
24. Rao CN, Lakka SS, Kin Y et al. Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin. Cancer Res. 7(3), 570-576 (2001).
25. Wu D, Xiong L, Wu S, Jiang M, Lian G, Wang M. TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer. Lung Cancer doi:10.1016/j. lungcan.2011.09.005 (2011) (Epub ahead of print). Discusses how TFPI-2 methylation may serve as a lung cancer prognosis marker.
26. Wong CM, Ng YL, Lee JM et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 45(5), 1129-1138 (2007).
27. Guo H, Lin Y, Zhang H et al. Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol. Biol. 8, 110 (2007).
28. Glockner SC, Dhir M, Yi JM et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 69(11), 4691-4699 (2009). Suggests TFPI-2 methylation is a colorectal cancer detection marker in stool sample.